Tenofovir-Containing Nucleoside/Nucleotide-Only Antiretroviral Maintenance Therapy: Decision Making and Virological Outcome

REFERENCES

• Margot NA, Isaacson E, McGowan I, Cheng A, Miller MD. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquir Immune Defic Syndr. 2003; 33(1):15–21.
   PubMed Web of Science ®Google Scholar
• Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fuma-rate: a nucleotide reverse transcriptase inhibitor for the treat-ment of HIV infection. Clin Ther. 2002;24(10):1515–1548.
   PubMed Web of Science ®Google Scholar
• Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002; 16(9):1257–1263.
   PubMed Web of Science ®Google Scholar
• Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS. 2002;16(9):1227–1235.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2)1 91–201.
   Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–260.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189(7):1185–1192.
   PubMed Web of Science ®Google Scholar
• Podzamczer D, Ferrer E, Gatell JM, et al. Early virological failure with a combination of tenofovir, didanosine and efavirenz. Antivir Ther. 2005;10(1):171–177.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Rodriguez AE, Weinberg WG, et al. Early viro-logic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis. 2005;192(11)1 921–1930.
   Web of Science ®Google Scholar
• Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet. 2003;362(9400)1 979–1980.
   Web of Science ®Google Scholar
• Perez-Elias MJ, Moreno S, Gutierrez C, et al. High virologi-cal failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir. AIDS. 2005;19(7):695–698.
   PubMed Web of Science ®Google Scholar
• Sudre P, Rickenbach M, Taffé P, et al. Clinical epidemiol-ogy and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988–2000. Schweiz Med Wochenschr. 2000;130(41)1 493–1500.
   Google Scholar
• Mauss S, Milinkovic A, Hoffmann C, et al. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. AIDS. 2005;19(1):101–102.
   PubMed Web of Science ®Google Scholar
• Masquelier B, Tamalet C, Montes B, et al. Genotypic deter-minants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-ex-perienced patients. Antivir Ther. 2004;9(3):315–323.
   PubMed Web of Science ®Google Scholar
• McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing inten-sification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2004;37(3):1340–1350.
   PubMed Web of Science ®Google Scholar
• Miller MD. K65R, TAMs and tenofovir. AIDS Rev. 2004;6(1):22–33.
   PubMed Web of Science ®Google Scholar
• Miller MD, Margot N, Lu B, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis. 2004;189(5):837–846.
   PubMed Web of Science ®Google Scholar
• DeChristoforo R, Penzak SR. Tenofovir: a nucleotide ana-logue reverse-transcriptase inhibitor for treatment of HIV infection. Am J Health Syst Pharm. 2004;61(1):86–98.
   PubMed Web of Science ®Google Scholar
• Garcia-Lerma JG, Maclnnes H, Bennett D, et al. A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J ViroL 2003;77(10):5685–5693.
   PubMed Web of Science ®Google Scholar
• Valer L, Martin-Carbonero L, De Mendoza C, Corral A, Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS. 2004;18(15):2094–2096.
   PubMed Web of Science ®Google Scholar
• Torti C, Quiros-Roldon E, Regazzi M, et al. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther. 2005 ;10 (4): 505–513 .
   PubMed Web of Science ®Google Scholar
• Parikh UM, Koontz DL, Chu CK, Schinazi RF, Mellors JW. In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother. 2005;49(3):1139–1144.
   PubMed Web of Science ®Google Scholar
• Wirden M, Marcelin AG, Simon A, et al. Resistance muta-tions before and after tenofovir regimen failure in HIV-1 infected patients. J Med ViroL 2005;76(3):297–301.
   PubMed Web of Science ®Google Scholar
• Delaunay C, Brun-Vezinet F, Landman R, et al. Compara-tive selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). J ViroL 2005;79(15):9572–9578.
   PubMed Web of Science ®Google Scholar
• Latham V, Stebbing J, Mandalia S, et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother. 2005;56(1):186–189.
   PubMed Web of Science ®Google Scholar
• Moyle G, Higgs C, Teague A, et al. An open-label, random-ized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther. 2006;11(1):73–78.
   PubMed Web of Science ®Google Scholar
• Stefanski KE, Tracy CS, Upshur RE. Sources of evidence in HIV/AIDS care: pilot study comparing family physicians and AIDS service organization staff. BMC Health Serv Res. 2004;4(1):18.
   PubMed Web of Science ®Google Scholar
• Opravil M, Hirschel B, Lazzarin A, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis. 2002;185(9):1251–1260.
   PubMed Web of Science ®Google Scholar
• Opravil M, Baumann D, Chave JP, et al. Long-term efficacy after switch from protease inhibitor-containing highly ac-tive antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS. 2004;18(16):2213–2215.
   PubMed Web of Science ®Google Scholar